Paul Segbers
YOU?
Author Swipe
View article: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma Open
Despite the improvement, approximately 60% of patients with relapsed or refractory (r/r) aggressive B cell lymphoma (B-NHL) do not achieve durable benefit from CAR-T cell therapy. To elucidate factors associated with CAR-T therapy resistan…
View article: O-10.02 Targeting CSF1R<sup>+</sup> myelo-monocytic cells enhances CAR-T cell response in B cell lymphoma
O-10.02 Targeting CSF1R<sup>+</sup> myelo-monocytic cells enhances CAR-T cell response in B cell lymphoma Open
View article: An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL Open
View article: Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCL
Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCL Open
Introduction: Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cell therapy have strongly improved the outcome of patients with diffuse large cell lymphoma (DLBCL) that are relapsed or refractory after standard chemo-immu…